预测无活动性癌症VTE患者抗凝3月后复发的新型动态风险评分
模型校准良好(斜率0.99),C统计量0.65,可识别抗凝3月后10年内的复发风险。
要点
- 动态评分含19个预测因子,其中13个增加、6个降低复发风险。
- 预测与观察风险校准良好(斜率0.99,95%CI 0.94-1.04)。
- 区分度稳定(C统计量0.65,95%CI 0.64-0.66)持续10年。
核心结论
- 动态风险评分可有效识别抗凝3月后无活动性癌症VTE患者的复发风险,并支持10年管理决策。
研究设计与样本
- 回顾性队列研究,使用英国临床实践研究数据链(2001-2020)中首次VTE且接受3个月抗凝的患者。
主要发现
- 复发VTE发生率为2.01/100人年。
- 模型含19个预测因子,13个与复发风险增加相关,6个与降低相关。
- 校准斜率0.99(95%CI 0.94-1.04),C统计量0.65(95%CI 0.64-0.66)10年稳定。
- 10年内复发风险下降,但每年内评分越高风险越高(第一年0.92%-21.23%,对应-5至+8分)。
临床怎么用
- 可用于抗凝3月后评估复发风险,辅助决定治疗时长和策略调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Predicting the risk of recurrent venous thromboembolism (rVTE) during and after anticoagulation is complex. Current models do not adapt to changing patient conditions, fail to account for the direct impact of anticoagulation in real-world settings, and are often derived without concurrent data on major bleeding. OBJECTIVES: To develop a dynamic, broad, treatment-adjusted risk score for rVTE. METHODS: We analyzed data from a retrospective cohort of patients from the UK Clinical Practice Research Datalink (2001-2020) with a first venous thromboembolism (VTE) who received 3 months of anticoagulation. rVTE risk was modeled using baseline and time-varying covariates (post-VTE). Hazard ratios with 95% CIs were estimated; a Fine-Gray model identified predictors. A scoring scheme was developed from subdistribution hazard ratios, with discrimination (C-statistic) estimated via cross-validation. RESULTS: A total of 51 465 patients with VTE were included; 4041 cases of rVTE occurred over 200 698 person-years. rVTE incidence was 2.01 per 100 person-years. The model included 19 predictors, of which 13 were associated with increased rVTE risk and 6 with decreased rVTE risk. Risk correlated well with outcomes; calibration showed good agreement between predicted and observed risks (calibration slope, 0.99 [95% CI, 0.94-1.04]). rVTE risk decreased over 10 years, but within each year, higher scores were associated with higher risk (0.92%-21.23% in the first year [-5 to +8 points]). The C-statistic (0.65 [95% CI, 0.64-0.66]) was stable over 10 years. CONCLUSION: Our dynamic risk score effectively identifies the risk of rVTE after 3 months of treatment and supports ongoing management over 10 years, aiding clinical decision-making regarding treatment duration and strategy adjustments as patient characteristics and comorbidities evolve.
引用
- Cohen AT, Choudhuri S, Khan I, et al. A novel dynamic risk score to predict venous thromboembolism recurrences after 3 months of anticoagulation in patients with incident venous thromboembolism and without active cancer. J Thromb Haemost. 2026. PMID: 42315028. doi:10.1016/j.jtha.2026.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。